Compared to Estimates, Sight Sciences (SGHT) Q2 Earnings: A Look at Key Metrics

Sight Sciences (SGHT) reported Q2 2025 revenue of $19.56 million, an 8.5% year-over-year decline, yet this significantly exceeded the Zacks Consensus Estimate of $18.11 million by 8.06%. EPS improved to -$0.23 from -$0.25 year-over-year, also surprising positively by 8%. The revenue beat was primarily driven by the Surgical Glaucoma segment, which posted $19.23 million, surpassing estimates despite a 5% YoY decline, while the smaller Dry Eye segment saw a substantial 70.4% YoY revenue decrease. Shares have outperformed the broader market, returning +4.6% over the past month, and maintain a Zacks Rank #2 (Buy), suggesting potential near-term outperformance.

Analysis

Sight Sciences (SGHT) presented a mixed financial picture for Q2 2025, defined by a notable top-line contraction offset by significant outperformance against analyst estimates. The company reported a year-over-year revenue decline of 8.5% to $19.56 million, yet this figure surpassed the Zacks Consensus Estimate by 8.06%. Similarly, EPS improved to -$0.23 from -$0.25 in the prior year, beating expectations by 8%. A segmental analysis reveals this performance was driven almost entirely by the core Surgical Glaucoma business, which generated $19.23 million in revenue. While this was down 5% year-over-year, it comfortably beat the $17.88 million analyst forecast. Conversely, the Dry Eye segment has effectively collapsed, with revenue plummeting 70.4% year-over-year to just $0.33 million. Despite the negative growth, the market has responded positively to the earnings surprise, with the stock returning +4.6% over the past month, outperforming the S&P 500. This, combined with a Zacks Rank #2 (Buy), suggests investors are prioritizing the company's ability to exceed lowered expectations over the underlying revenue decline.

Key Decisions for Investors

• Investors should primarily assess the health of the Surgical Glaucoma segment, as its ability to beat estimates is driving the current positive sentiment, while considering the Dry Eye segment's revenue to be largely immaterial given its 70.4% YoY collapse.
• Given the conflicting signals of a strong earnings beat against a backdrop of an 8.5% revenue decline, it is critical to monitor for signs of top-line stabilization in subsequent quarters to validate a longer-term investment thesis.
• Considering the stock's recent outperformance and its Zacks Rank #2 (Buy), short-term momentum appears positive, but investors should weigh this against the fundamental risk posed by significant year-over-year revenue contraction.